BLAINJECTIONINJECTABLE
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETACRIT (epoetin alfa-epbx) is a biosimilar erythropoiesis-stimulating agent administered by injection that stimulates red blood cell production. It is indicated for patients with anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions requiring erythropoiesis support. The drug works by mimicking endogenous erythropoietin to increase hemoglobin and reduce transfusion requirements.
$25MPart D
PeakStable
Product is at peak revenue stage with modest Part D spending, suggesting a mature, stable commercial team focused on maintaining market share rather than rapid expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology
Started Jun 2012
2,167 enrolled
Chemotherapy-induced Anemia
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Started Dec 2010
291 enrolled
Chemotherapy-induced Symptomatic AnaemiaSolid TumoursMalignant Lymphomas+1 more
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
Started Jul 2010
4,501 enrolled
Renal AnemiaPregnancyLactation
Career Relevance
Working on RETACRIT offers exposure to biosimilar commercialization, managed care negotiations, and payer strategy within Pfizer's mature oncology and nephrology franchises. Career growth is tied to defending market share and expanding formulary access rather than driving new indication launches.
Worked on RETACRIT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.